Overview
Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.

Coverage Guidelines

Baqsimi
Authorization may be granted for members who are currently receiving treatment with Baqsimi, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs OR
Authorization may be granted if the member meets all following criteria and documentation has been submitted:
1. The member has documented diagnosis of severe hypoglycemia with diabetes
2. The member age is ≥ 4 years
3. The member has had an inadequate response or contraindication to glucagon injection (powder for reconstitution)

Gvoke
Authorization may be granted for members who are currently receiving treatment with Gvoke, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs OR
Authorization may be granted if the member meets all following criteria and documentation has been submitted:
1. The member has documented diagnosis of severe hypoglycemia with diabetes
2. The member age is ≥ 2 years
3. The member has had an inadequate response or contraindication to glucagon injection (powder for reconstitution)

Limitations
Approvals will be granted for 36 months

References

Review History
05/20/2020 – Reviewed and approved May P&T. Effective 5/01/20

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.